Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Trial of Autologous Dendritic Killer Cell (DKC) in Metastatic Solid Tumors
NCT02882659Phase 1Unknown
- Sponsor
- FullHope Biomedical Co., Ltd.
- Start
- Aug 2014
- Primary completion
- Jan 2016
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
01
Overview
Phase 1, open-label, single-arm trial of FHCT001 in solid tumor, colorectal cancer (CRC), gastric cancer (GC) and 3 more, sponsored by FullHope Biomedical Co., Ltd. Primary endpoints: Safety of DKC as assessed by adverse event (AE), Safety of DKC as assessed by serious adverse event (SAE) and 2 more. Status: unknown.
02
Drugs
FHCT001
03
Conditions
solid tumorcolorectal cancer (CRC)gastric cancer (GC)pancreatic cancer (PC)cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT02882659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02882659.